Modality
mAb
MOA
AHRant
Target
Nectin-4
Pathway
Wnt
ET
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
~Apr 2019
→ ~Jul 2020
Phase 2
Oct 2020
→ May 2030
Phase 2Current
NCT04223571
2,016 pts·ET
2020-10→2027-01·Not yet recruiting
NCT04792856
2,930 pts·ET
2021-08→2030-05·Active
4,946 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-01-129mo awayPh2 Data· ET
2030-05-114.1y awayPh2 Data· ET
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2
Not yet…
P2
Active
Catalysts
Ph2 Data
2027-01-12 · 9mo away
ET
Ph2 Data
2030-05-11 · 4.1y away
ET
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04223571 | Phase 2 | ET | Not yet recr... | 2016 | Safety |
| NCT04792856 | Phase 2 | ET | Active | 2930 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| NTL-2576 | Intellia | NDA/BLA | SGLT2 |